New combo therapy aims to outsmart drug-resistant lung cancer
NCT ID NCT07486648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding capivasertib to osimertinib can help people with a specific type of advanced lung cancer whose disease has worsened after initial treatment. About 53 adults with EGFR-mutant NSCLC and additional PIK3CA/AKT1/PTEN gene changes will receive the two drugs together. The goal is to find a safe dose and see if the combination shrinks tumors or delays progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NON-SMALL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
Taiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••